These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37180706)

  • 1. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis.
    Tang Q; Wu D; Huang H; Fang H; Wu Y; Liu F; Li N
    Front Pharmacol; 2023; 14():1093194. PubMed ID: 37180706
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis.
    Huang S; Huang Y; Li C; Liang Y; Huang M; Luo R; Liang W
    Front Immunol; 2023; 14():1332213. PubMed ID: 38264649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis.
    Yang Y; Pang P; Xie Z; Wang N; Liang H; Zhao L
    Transl Cancer Res; 2020 May; 9(5):3231-3241. PubMed ID: 35117689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review.
    Xu T; Liu Y; Lu X; Liang J
    Front Immunol; 2022; 13():1039020. PubMed ID: 36439117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis.
    Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J
    Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis.
    Feng Y; Guo K; Jin H; Jiang J; Wang M; Lin S
    Front Immunol; 2023; 14():1269067. PubMed ID: 38250059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews.
    Ou SL; Luo J; Wei H; Qin XL; Du SY; Wang S; Jiang Q
    Front Immunol; 2022; 13():953761. PubMed ID: 35911744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis.
    Pei WG; Chen WZ; Wu YK; Tan SX; Jie ZG
    World J Gastrointest Oncol; 2023 Feb; 15(2):352-367. PubMed ID: 36908315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis.
    Huang YF; Xie WJ; Fan HY; Du J
    Front Oncol; 2019; 9():972. PubMed ID: 31632907
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
    Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis.
    Zhao P; Zhao T; Yu L; Ma W; Liu W; Zhang C
    Front Oncol; 2024; 14():1381250. PubMed ID: 38756658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
    Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
    Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
    Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
    EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma.
    Wang B; Hao X; Yan J; Li X; Zhao M; Han T
    J Transl Int Med; 2024 Jun; 12(3):225-243. PubMed ID: 39081283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.